Active substances: Norfloxacin
Search Menu Abstract Background. Uncomplicated lower urinary tract infection LUTI is one of the most common infections treated in general practice. For this reason norfloxacin and other fluoroquinolones are contraindicated during pregnancy due to the risk of spontaneous abortions and birth defects.
The manufacturer only recommends use of norfloxacin during pregnancy when benefit outweighs risk. Ciprofloxacin is being licensed for the treatment of Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli and Inhalational Anthrax post-exposure and levofloxacin was recently licensed for the treatment of Inhalational Anthrax post-exposure.
However, the Fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK. Adverse effects In general, fluoroquinolones are well tolerated, with most side-effects being mild to moderate.
The overall rate of adverse events in patients treated with fluoroquinolones is roughly similar to that seen in patients treated with other antibiotic classes.
Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin.
The range of working experience in general practice was from 1 to 40 years a mean of 16 years.
Fifty-five 42. The participants spent on average 8 days a year on continuing medical education CME. A majority of them 63.
The average working time was 39 h per week, and on average 45 patients per day were seen.
The average list size was 1866 patients. Ninety-three 72. Sixty 46. As many as 23 17.
Microscopic urine sediment analysis was ordered again by eight GPs and urine culture by seven.
In 99. Sixteen different brand names were used; the list of prescribed drugs according to the generics is given in Table 1.
In addition to a prescribed drug. In addition. A total of 53.
All GPs gave the patient advice regarding non-pharmacological treatment, which resulted in a long list of different advisory options Table 2. Blood samples for determination of concentrationof 4-fluoroquinolones in plasma were obtained atzero time pre-drug and at 0.
Afterrinsing the mouth with water, samples of unstimu-lated mixed saliva were collected over a 2-minperiod, at the same times as blood samples weredrawn. The volume of collected saliva was mea-sured to allow calculation of salivary flow rate.
ThepH of saliva samples was measured as soon asthe samples were obtained. The plasma and salivasamples were kept frozen at 20 C prior toanalysis. Analytical Procedure 4-Fluoroquinolones concentrations in plasma andsaliva samples were measured by the reversedphase HPLC method after deproteinization withacetonitrile.